![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » OncoSil’s Pancreatic Cancer Treatment Gets CE Mark
OncoSil’s Pancreatic Cancer Treatment Gets CE Mark
OncoSil Medical has earned a CE Mark for its OncoSil implant used to treat pancreatic cancer alongside chemotherapy.
The radioactive implant is placed directly in a patient’s pancreatic tumor using endoscopic ultrasound. It can also be used to treat other solid tumor types such as liver and biliary duct cancer.
OncoSil previously received a breakthrough device designation from the FDA.
Upcoming Events
-
11Jul
-
18Jul
-
21Oct